
BXRX
Healthcare · Biotechnology · $950,329 market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 16, 2023 | After the close | -2.04 | -1.52 | +25.5% |
| May 12, 2023 | After the close | 5.75 | -3.91 | -168.0% |
| Feb 23, 2023 | After the close | -9.76 | -12.33 | -26.3% |
| Nov 8, 2022 | After the close | -21.20 | -26.40 | -24.5% |
| Aug 11, 2022 | After the close | -50.80 | -42.00 | +17.3% |
| May 4, 2022 | After the close | -74.00 | -126.80 | -71.4% |
| Mar 16, 2022 | After the close | 59.00 | 401.20 | +580.0% |
| Nov 4, 2021 | After the close | -217.00 | -280.00 | -29.0% |
| Aug 5, 2021 | After the close | -280.00 | -322.00 | -15.0% |
| May 5, 2021 | After the close | -270.67 | -378.00 | -39.7% |
| Feb 16, 2021 | After the close | -849.33 | -770.00 | +9.3% |
| Nov 9, 2020 | After the close | -1031.33 | 868.00 | +184.2% |
| Aug 10, 2020 | After the close |
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an…
| -914.67 |
| -2408.00 |
| -163.3% |
| May 8, 2020 | After the close | -2501.33 | -5418.00 | -116.6% |
| Feb 13, 2020 | After the close | -1311.33 | -1092.00 | +16.7% |
| Nov 12, 2019 | After the close | -1.14 | -1.84 | -61.4% |
| Aug 28, 2019 | Time not confirmed | — | -0.92 | — |